Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma

about

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma

Item

http://www.wikidata.org/entity/Q58568655

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@en

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@nl

type

Item

label

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@en

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@nl

prefLabel

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@en

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@nl

P1476

Implications of Programmed Dea ...... lear Cell Renal Cell Carcinoma

@en

P2093

Charles C Peyton

http://www.w3.org/2001/XMLSchema#string

Dominic H Tang

http://www.w3.org/2001/XMLSchema#string

Jasreman Dhillon

http://www.w3.org/2001/XMLSchema#string

Juan Chipollini

http://www.w3.org/2001/XMLSchema#string

Mounsif Azizi

http://www.w3.org/2001/XMLSchema#string

Philippe E Spiess

http://www.w3.org/2001/XMLSchema#string

P2860

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PD-1 and its ligands in tolerance and immunity

Cancer statistics, 2016

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Surveillance strategies for renal cell carcinoma patients following nephrectomy.

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

PD-L1 expression in nonclear-cell renal cell carcinoma.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Long-term outcomes of the surgical management of renal cell carcinoma.

P304

6-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15586/JKCVHL.2018.107

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30386718

http://www.w3.org/2001/XMLSchema#string

P932

6186848

http://www.w3.org/2001/XMLSchema#string